Jubilant Pharmova to raise ₹800 crore through debut bond offering

What Happened

Jubilant Pharmova announced a debut bond offering that aims to raise up to ₹800 crore in the domestic market. The issue comprises a base tranche of ₹400 crore and an equal greenshoe option that can be exercised to double the amount if investor demand warrants it.

Allocation

The company said the money will be used mainly for capital expenditure and for its upcoming expansion plans. By directing funds to new plant and equipment, the firm hopes to increase production capacity and support growth in its pharmaceutical and agro‑chemical businesses. The capital will support the company's plan to expand its manufacturing footprint across the country.

Subscription

Jubilant Pharmova expects most of the bond to be taken up by mutual funds and asset managers, making these institutional investors the primary subscribers. The focus on mutual funds and asset managers reflects the company's aim to secure long‑term financing from stable institutional sources. The participation of such investors signals confidence in the company’s credit profile and its strategy to tap the debt market.

Context

Corporate bond issues let firms raise large sums without issuing new equity. A greenshoe option gives the issuer flexibility to increase the size of the issue when demand is strong. In India, mutual funds and asset managers are typical buyers of domestic bonds, providing liquidity and stable funding sources. Such domestic bond issuances have grown in popularity as companies seek alternative funding routes.